Download the Prospectus
Pre Money Equity Valuation
$18,402,860
Min Raise
$6,000,000
Max Raise
$7,000,000
Estimated Close
2020-10-13
Issue Type
IPO
Lead Manager
Baker Young Ltd
Type of Securities
Shares
Market Cap Max
$25,402,860
Key Executives
Brian Leedman, Raanan Shamir, Hadassa Bymel, Moshe Phillip, Liron Fendell, Kinneret Savitzky, Anton Uvarov, Amir Zaidman
Company Address
4 Berkovich Street Tel Aviv 6423806 Israel
Exchange
ASX
Chairman's Letter

Dear Investors
On behalf of the Board of Nutritional Growth Solutions Ltd (NGS), it is my pleasure to present this Prospectus for our initial
public offer.
NGS develops, produces and sells clinically tested nutritional supplement formulae for children following 20 years of
medical research into paediatric nutrition at Schneider Children’s Medical Centre, Israel’s largest paediatric hospital.
In a prospective, randomised, double-blind, placebo-controlled study, the company’s lead product, Healthy Height®
was found to have a significant effect on children’s height and weight, compared to children consuming the control
supplement. Healthy Height® is currently sold in the USA, Canada, and Israel, exclusively through online sales channels.
Implementation of our strategy for entry into China has now been initiated, with entry into other lucrative Asian markets
also planned for the future.
New clinical studies are underway to support additional product launches, with the Healthy Height® Junior Growth
Formula for children who are 10 years or older, and a further formula, the Sports Formula, to support athletic
performance of active children.
The nutritional supplements market has experienced tremendous growth in recent years, but most attention has been
focused on adult users and children under three years of age. The three to twelve year old consumers represent a large
market opportunity and NGS is highly differentiated from its competitors with clinically tested products and an expanding
product portfolio to capture this market opportunity.
The purpose of the Offer is to raise up to A$7,000,000 (before associated costs) via the issue of up to 35,000,000 Shares in
the capital of the Company at an issue price of A$0.20 per Share.
This Prospectus includes detailed information about the Offer, including the material risks associated with an investment
in the Company.
On behalf of the board of Directors, I present the Offer to you and recommend that you read this Prospectus in full. I look
forward to welcoming you as a supportive shareholder of the Company.
Yours sincerely,
9
LETTER FROM THE CHAIR
Dear Investors
On behalf of the Board of Nutritional Growth Solutions Ltd (NGS), it is my pleasure to present this
Prospectus for our initial public offer.
NGS develops, produces and sells clinically tested nutritional supplement formulae for children following
20 years of medical research into paediatric nutrition at Schneider Children’s Medical Centre, Israel’s
largest paediatric hospital.
In a prospective, randomised, double-blind, placebo-controlled study, the company’s lead product, Healthy
Height® was found to have a significant effect on children’s height and weight, compared to children
consuming the control supplement. Healthy Height® is currently sold in the USA, Canada, and Israel,
exclusively through online sales channels.
Implementation of our strategy for entry into China has now been initiated, with entry into other lucrative
Asian markets also planned for the future.
New clinical studies are underway to support additional product launches, with the Healthy Height® Junior
Growth Formula for children who are 10 years or older, and a further formula, the Sports Formula, to support
athletic performance of active children.
The nutritional supplements market has experienced tremendous growth in recent years, but most attention
has been focused on adult users and children under three years of age. The three to twelve year old
consumers represent a large market opportunity and NGS is highly differentiated from its competitors with
clinically tested products and an expanding product portfolio to capture this market opportunity.
The purpose of the Offer is to raise up to A$7,000,000 (before associated costs) via the issue of up to
35,000,000 Shares in the capital of the Company at an issue price of A$0.20 per Share.
This Prospectus includes detailed information about the Offer, including the material risks associated with
an investment in the Company.
On behalf of the board of Directors, I present the Offer to you and recommend that you read this Prospectus
in full. I look forward to welcoming you as a supportive shareholder of the Company.
Yours sincerely,
Brian Leedman
Non-executive Chairman
Brian Leedman
Non-executive Chairman